DEX Protocol Injective Raises $40M From Jump Crypto, Brevan Howard Unit

The project will use the funds to boost the utility of the INJ Token.

By Michael Bellusci

Aug 10, 2022 at 1:00 p.m. UTC

Updated Aug 10, 2022 at 2:20 p.m. UTC

Venture capital keyboard — (Peter Dazeley/Getty Images)

Michael Bellusci

Michael Bellusci is CoinDesk's crypto reporter focused on public companies and digital asset firms.

Follow @mikeybellusci on Twitter

Decentralized smart contracts platform Injective raised $40 million in a funding round that was led by Jump Crypto, the company said on Wednesday.

BH Digital, the crypto and digital asset unit of investment firm Brevan Howard, also participated in the round.

Injective said it will use the funding to boost utility for its native INJ Token, for liquidity for existing decentralized apps built on Injective and to support new dapps on the platform.

“With Jump as a major force in the crypto ecosystem, the partnership will be focused on expanding Injective’s network and further providing shared liquidity across the Injective ecosystem,” Eric Chen, CEO of Injective Labs, said in a statement.

Injective sets out to resolve scalability issues and bottlenecks that can mar the user experience on decentralized exchanges (DEXs). The company started trading in tokenized stocks of major public companies in 2020.

“Injective offers these institutions an out-of-the-box solution that can be leveraged to build any finance app,” Jump Crypto President Kanav Kariya said in the statement.

DISCLOSURE

Please note that our privacy policy, terms of use, cookies, and do not sell my personal information has been updated.

The leader in news and information on cryptocurrency, digital assets and the future of money, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups. As part of their compensation, certain CoinDesk employees, including editorial employees, may receive exposure to DCG equity in the form of stock appreciation rights, which vest over a multi-year period. CoinDesk journalists are not allowed to purchase stock outright in DCG.